APC-8000 – Tadalafil
If approved, APC-8000 will be a fast-disintegrating sublingual tablet containing tadalafil to treat erectile dysfunction.
Potential Indication: Erectile Dysfunction
Tadalafil (Cialis®) is in a class of drugs called phosphodiesterase-5 (PDE5) inhibitors which includes, among others, sildenafil (Viagra®) and vardenafil (Levitra®). All three drugs of these oral tablets are FDA approved and clinically indicated for the treatment of ED.
Adamis’ goal in development and clinical testing will be to demonstrate comparability to Cialis® and additional potential benefits of a rapidly acting sublingual formulation.
According to the Massachusetts Male Aging Study, as many as 52 percent of men experience erectile dysfunction, with it affecting 40 percent of men at age 40, and 70 percent of men at age 70.